Collection of Blood From Patients With Cancer

Background:

- Correlative studies performed on biospecimens of human subjects can be used to

investigate the biology of solid tumors, inform the development of new strategies

for treating those cancers, and evaluate these new therapeutic approaches. Specific

areas of interest include, but are not limited to:

- the underlying mechanisms of tumor-specific immune response and suppression in

cancer patients

- genetic and molecular profiling of tumors through circulating tumor cell (cTC),

circulating DNA, and tissue analysis

- investigation of potential early diagnostic and prognostic indicators for solid

tumors such as cTCs and miRNA expression of serum exosomes

- identification of mechanisms of drug-related adverse events and correlation with

clinical parameters

- the role of commensal gut microbiota in both the innate and adaptive responses to

tumors as well as with the use of anticancer agents

Objectives:

- Analyze biospecimens such as tissue, urine, saliva, stool and blood components,

which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and

circulating tumor cells (cTC), of human subjects.

- Correlate analysis results with clinical parameters such as demographics,

toxicities, and treatment outcomes.

- Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced

mutational analysis.

Eligibility:

- Patients and healthy volunteers whose biospecimens are of interest to NIH

investigators.

- 18 years of age or older.

Design:

- Cases will be evaluated by NCI or Interventional Radiology, NIH Clinical Center

personnel. Blood, tissue, urine, saliva or other samples may be collected at the initial

visit and at follow-up visits.